Federico Cappuzzo
#148,746
Most Influential Person Now
Researcher
Federico Cappuzzo's AcademicInfluence.com Rankings
Federico Cappuzzocomputer-science Degrees
Computer Science
#7664
World Rank
#8068
Historical Rank
Computational Linguistics
#1570
World Rank
#1587
Historical Rank
Machine Learning
#2904
World Rank
#2940
Historical Rank
Artificial Intelligence
#3199
World Rank
#3246
Historical Rank
Download Badge
Computer Science
Federico Cappuzzo's Degrees
- PhD Computer Science University of California, Berkeley
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of Milan
Similar Degrees You Can Earn
Why Is Federico Cappuzzo Influential?
(Suggest an Edit or Addition)Federico Cappuzzo's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling (2007) (3564)
- First-line crizotinib versus chemotherapy in ALK-positive lung cancer. (2014) (2577)
- Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC (2018) (2238)
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. (2010) (1968)
- Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. (2005) (1575)
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. (2015) (1280)
- Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. (2010) (1226)
- Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer (2012) (1151)
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial (2014) (959)
- Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer (2010) (841)
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. (2019) (806)
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab (2011) (577)
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. (2019) (560)
- Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. (2009) (523)
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients (2014) (506)
- A Genomics-Based Classification of Human Lung Tumors (2013) (403)
- Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer (2012) (403)
- Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. (2004) (392)
- Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. (2005) (371)
- Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. (2004) (337)
- Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. (2015) (318)
- The Increasing Dominance of Teams in Production of Knowledge (2011) (317)
- MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. (2009) (292)
- Consensus for EGFR Mutation Testing in Non-small Cell Lung Cancer: Results from a European Workshop (2010) (289)
- Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. (2006) (289)
- Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. (2011) (276)
- EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. (2008) (268)
- Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. (2005) (263)
- Targeting MET in Lung Cancer: Will Expectations Finally Be MET? (2017) (255)
- Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer (2009) (252)
- Role of gemcitabine in cancer therapy. (2005) (248)
- Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. (2016) (246)
- Frequent mutations in chromatin-remodeling genes in pulmonary carcinoids (2014) (230)
- HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. (2006) (227)
- Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. (2007) (226)
- Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. (2008) (219)
- Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous Non-Small-Cell Lung Cancer (IMpower131): Results From a Randomized Phase III Trial. (2020) (213)
- IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. (2018) (212)
- Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial. (2008) (207)
- Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. (2003) (205)
- Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. (2016) (204)
- Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. (2018) (191)
- Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients (2008) (179)
- Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. (2009) (161)
- Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. (2011) (160)
- SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. (2016) (143)
- Bronchioloalveolar Carcinoma and Lung Adenocarcinoma: The Clinical Importance and Research Relevance of the 2004 World Health Organization Pathologic Criteria (2006) (140)
- Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. (1996) (134)
- EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects. (2012) (127)
- EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer (2009) (124)
- HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients (2013) (120)
- Epidermal growth factor receptor inhibition in lung cancer: status 2012. (2013) (119)
- Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. (2016) (119)
- IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer. (2021) (111)
- Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. (2011) (111)
- Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials (2008) (110)
- Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer (2012) (109)
- Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). (2003) (108)
- First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014) (2014) (103)
- Epidermal Growth Factor Receptor Messenger RNA Expression, Gene Dosage, and Gefitinib Sensitivity in Non–Small Cell Lung Cancer (2006) (103)
- Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. (2009) (102)
- Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. (2012) (100)
- Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. (2019) (99)
- Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial (2019) (99)
- OP 85 Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab (2011) (98)
- Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib With Chemotherapy: Results From PROFILE 1014 (2018) (98)
- Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program (2019) (98)
- Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. (2006) (94)
- Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. (2009) (89)
- ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment. (2014) (88)
- EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) (2007) (87)
- Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma (2008) (87)
- Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations (2016) (83)
- Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer (2019) (80)
- HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients (2005) (80)
- Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA (2016) (78)
- Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study. (2013) (77)
- EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer (2007) (77)
- Glutamine supplementation in cancer patients receiving chemotherapy: a double-blind randomized study. (1997) (77)
- Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. (2018) (76)
- Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. (2010) (74)
- microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers (2015) (71)
- Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. (2018) (69)
- Randomized phase II study of danusertib in patients with metastatic castration‐resistant prostate cancer after docetaxel failure (2013) (68)
- Future scenarios for the treatment of advanced non-small cell lung cancer: focus on taxane-containing regimens. (2010) (68)
- Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues. (2011) (67)
- IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. (2018) (64)
- IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. (2021) (62)
- Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. (2014) (62)
- Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC. (2009) (61)
- HER2 and lung cancer (2013) (60)
- Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC) (2004) (59)
- Prognostic and Predictive Value of K-RAS Mutations in Non-Small Cell Lung Cancer (2012) (58)
- Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features. (2013) (54)
- Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations (2018) (54)
- Blockage of interleukin-1β with canakinumab in patients with Covid-19 (2020) (53)
- EGFR FISH versus mutation: different tests, different end-points. (2008) (53)
- Clinical implications of MET gene copy number in lung cancer. (2010) (53)
- Assessment of tumor response in malignant pleural mesothelioma. (2007) (53)
- Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% (2020) (52)
- MYC and EIF3H Coamplification Significantly Improve Response and Survival of Non-small Cell Lung Cancer Patients (NSCLC) Treated with Gefitinib (2009) (52)
- ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS). (2019) (51)
- Clinical experience with gefitinib: an update. (2006) (51)
- Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study. (2021) (51)
- Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. (2007) (49)
- MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies. (2014) (48)
- cMET Exon 14 Skipping: From the Structure to the Clinic. (2016) (48)
- Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA‐bulky N2 and Stage IIIB nonsmall cell lung carcinoma (2003) (47)
- Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung Cancer (2004) (46)
- Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus. (2015) (45)
- OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057 (2017) (45)
- Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC). (2006) (45)
- Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. (2012) (45)
- Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer. (1995) (45)
- Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study (2011) (45)
- The neuropilin 2 isoform NRP2b uniquely supports TGFβ-mediated progression in lung cancer (2017) (43)
- Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. (2017) (43)
- Primary pulmonary meningioma: report of a case and review of the literature. (2008) (42)
- Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations (2019) (41)
- Targeted therapy for NSCLC with driver mutations (2013) (41)
- The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta-analysis of 50 studies with 11,383 patients. (2019) (41)
- Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes. (2020) (41)
- Targeting c-MET in the battle against advanced nonsmall-cell lung cancer (2013) (40)
- Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. (2017) (40)
- ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases (2003) (40)
- The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC (2011) (39)
- LBA1_PRPrimary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150) (2017) (39)
- Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. (2016) (38)
- K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value (2012) (38)
- Anaplastic lymphoma kinase gene rearrangements in cytological samples of non–small cell lung cancer: Comparison with histological assessment (2014) (37)
- cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance (2015) (34)
- Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population. (2019) (34)
- Onartuzumab in lung cancer: the fall of Icarus? (2015) (34)
- Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer (2013) (34)
- HER2 in solid tumors: more than 10 years under the microscope; where are we now? (2014) (34)
- Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer (2004) (33)
- A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. (2018) (33)
- Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology. (2012) (33)
- Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients. (2011) (33)
- Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance. (2006) (32)
- Strategies for improving outcomes in NSCLC: a look to the future. (2013) (31)
- Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer. (2016) (30)
- A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy. (2006) (30)
- Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer (2005) (29)
- Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Non–Small-Cell Lung Cancer (2015) (28)
- Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study (2021) (28)
- Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. (2021) (28)
- Abstract CT216: IMpower150 final analysis: Efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups (2020) (27)
- Rare mutations in non-small-cell lung cancer. (2013) (27)
- Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer (2005) (27)
- Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. (2014) (27)
- Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer (2016) (26)
- Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials. (2015) (26)
- A phase II study of RAD001 (R) (everolimus) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I) (2007) (26)
- Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial (2022) (26)
- Predicting clinical benefit from EGFR TKIs: Not all EGFR mutations are equal. (2006) (25)
- FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study (2014) (24)
- ALK gene rearrangements in unselected caucasians with non-small cell lung carcinoma (NSCLC). (2010) (24)
- Erlotinib in gliomas: should selection be based on EGFR and Akt analyses? (2005) (24)
- A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer. (2014) (24)
- OA14.02 IMpower131: Final OS Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC (2019) (24)
- Present and future treatment of advanced non-small cell lung cancer. (2002) (23)
- 134PD Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150) (2018) (23)
- Crizotinib: from discovery to accelerated development to front-line treatment. (2016) (23)
- Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. (2019) (23)
- Experience with erlotinib in the treatment of non-small cell lung cancer (2015) (23)
- Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer (2014) (22)
- Irreversible EGFR-TKIs: dreaming perfection. (2013) (22)
- Gemcitabine for the treatment of advanced nonsmall cell lung cancer (2009) (22)
- Medical treatment of brain metastases from solid tumours. (2000) (22)
- LBA50Overall survival (OS) for first-line crizotinib versus chemotherapy in ALK+ lung cancer: Updated results from PROFILE 1014 (2017) (22)
- Emerging drugs for small-cell lung cancer (2009) (21)
- Impact of biomarkers on non-small cell lung cancer treatment (2010) (21)
- Emerging drugs for small cell lung cancer – an update (2012) (21)
- Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib (2017) (21)
- Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): Results of Italian Rames Study. (2020) (20)
- Protein kinase inhibitors to treat non-small-cell lung cancer (2014) (19)
- Erlotinib in the first-line treatment of non-small-cell lung cancer (2013) (19)
- IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations. (2018) (19)
- Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC) (2018) (19)
- Crizotinib: from discovery to accelerated development to front-line treatment. (2018) (19)
- Clinical and biological effects of gefitinib in EGFR FISH positive/phospho-akt positive or never smoker non-small cell lung cancer (NSCLC): Preliminary results of the ONCOBELL trial. (2006) (19)
- Pharmacotherapy targeting the EGFR oncogene in NSCLC (2014) (18)
- Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis (2021) (18)
- Management of NSCLC: focus on crizotinib (2014) (18)
- 1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations (2020) (17)
- Cancer Stem Cells Sensitivity Assay (STELLA) in Patients with Advanced Lung and Colorectal Cancer: A Feasibility Study (2015) (17)
- Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies. (2018) (17)
- Let-7 g and miR-21 expression in non-small cell lung cancer : Correlation with clinicopathological and molecular features (16)
- Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study. (2015) (16)
- p95HER2 Truncated Form in Resected Non-small Cell Lung Cancer (2012) (16)
- KEAP1 and TP53 frame genomic, evolutionary and immunological subtypes of lung adenocarcinoma with different sensitivity to immunotherapy. (2021) (16)
- Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150. (2021) (16)
- Targeted therapies: Front-line therapy in lung cancer with mutations in EGFR (2011) (15)
- Exposure–response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer (2018) (15)
- Nivolumab in patients (pts) with advanced refractory squamous (SQ) non‐small cell lung cancer (NSCLC): 2‐year follow‐up from CheckMate 063 and exploratory cytokine profling analyses: 137O (2016) (15)
- Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer. (2003) (15)
- Prognostic Value of p16 Protein in Patients With Surgically Treated Non-small Cell Lung Cancer; Relationship With Ki-67 and PD-L1 (2020) (15)
- 22LBA Overall survival analyses from the SATURN phase III placebo-controlled study of erlotinib as first-line maintenance therapy in advanced non-small-cell lung cancer (NSCLC) (2009) (15)
- Gefitinib for non-small-cell lung cancer treatment (2011) (15)
- Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study (2019) (15)
- 1265P IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations (2020) (14)
- Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy (2020) (14)
- Evolution and future perspectives in the treatment of locally advanced non-small cell lung cancer. (2007) (14)
- EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center. (2016) (14)
- Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. (2019) (14)
- 9176 Biomarker analyses from SATURN, a phase III placebo-controlled study of erlotinib as first-line maintenance therapy for advanced NSCLC (2009) (14)
- 1225OOVERALL AND INTRACRANIAL (IC) EFFICACY RESULTS AND TIME TO SYMPTOM DETERIORATION IN PROFILE 1014: 1ST-LINE CRIZOTINIB VS PEMETREXED - PLATINUM CHEMOTHERAPY (PPC) IN PATIENTS (PTS) WITH ADVANCED ALK-POSITIVE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC). (2014) (14)
- Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies? (2016) (13)
- 1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial (2020) (13)
- Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series. (2014) (13)
- O-107 FISH and Immunohistochemistry (IHC) can be used to selectNSCLC patients, who will not benefit from gefitinib treatment (2005) (12)
- A noninterventional, multinational study to assess PD‐L1 expression in cytological and histological lung cancer specimens (2020) (12)
- Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer (Science Translational Medicine (2012) 4, (130er2)) (2011) (12)
- Development of gemcitabine in non-small cell lung cancer: the Italian contribution. (2006) (11)
- LBA11 IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen (2022) (11)
- Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer (2019) (11)
- An international consortium study in chemorefractory metastatic colorectal cancer (mCRC) patients (pts) to assess the impact of FCGR polymorphisms on cetuximab efficacy. (2011) (11)
- Nodal Upstaging Evaluation After Robotic-Assisted Lobectomy for Early-Stage Non-small Cell Lung Cancer Compared to Video-Assisted Thoracic Surgery and Thoracotomy: A Retrospective Single Center Analysis (2021) (10)
- IMpower150: analysis of efficacy in patients (pts) with liver metastases (mets) (2019) (10)
- Improved efficacy of gefitinib therapy in phospho-Akt positive patients with advanced non-small cell lung cancer. (2004) (10)
- Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts. (2020) (10)
- MET overexpression and gene amplification in NSCLC: a clinical perspective. (2013) (10)
- Meta-analysis of the predictive and prognostic value of erlotinib-related biomarkers in phase III, placebo-controlled trials in non-small cell lung cancer (NSCLC): Recommendations of the BioLOGUE advisors. (2011) (10)
- IMpower150: Exploratory analysis of brain metastases development. (2020) (9)
- Predictive Factors for Response and for Resistance to Tyrosine Kinase Inhibitor Therapy in Lung Cancer (2007) (9)
- 9158 A phase III study of erlotinib as maintenance therapy in NSCLC to delay progression following first-line chemotherapy (SATURN) (2009) (9)
- Oncological Outcomes of Robotic Lobectomy and Radical Lymphadenectomy for Early-Stage Non-Small Cell Lung Cancer (2022) (9)
- P2.01-15 Phase II Single Arm Study of CABozantinib in Non-Small Cell Lung Cancer Patients with MET Deregulation (CABinMET) (2019) (9)
- The role of cMet in non-small cell lung cancer resistant to EGFR-inhibitors: did we really find the target? (2014) (9)
- Epidermal Growth Factor Receptor Inhibition in Lung Cancer (2013) (9)
- Determining the appropriate treatment for different EGFR mutations in non-small cell lung cancer patients (2020) (8)
- Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM) (2019) (8)
- Gemcitabine in non-small cell lung cancer (2002) (8)
- Perspectives on salvage therapy for non-small-cell lung cancer. (2005) (8)
- Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study. (2014) (8)
- Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study (2014) (8)
- Emerging drugs for non-small cell lung cancer (2003) (8)
- Targeting MET in NSCLC: looking for a needle in a haystack. (2014) (8)
- Phase III clinical trials in chemotherapy-naive patients with advanced NSCLC assessing the combination of atezolizumab and chemotherapy (2016) (8)
- Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly (2015) (8)
- P1.01-053 Italian Nivolumab Expanded Access Programme (EAP): Data from Patients with Advanced Non-Squamous NSCLC and Brain Metastases (2017) (8)
- Insuline like growth factor receptor-1 (IGFR-1), MET, and BRAF and primary resistance to cetuximab therapy in colorectal cancer patients (2008) (8)
- Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges. (2007) (7)
- Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib (2019) (7)
- Circulating HPV DNA in the Management of Oropharyngeal and Cervical Cancers: Current Knowledge and Future Perspectives (2021) (7)
- Exposure-response relationship for ramucirumab (RAM) from the randomized, double-blind, phase III REVEL trial (docetaxel [DOC] vs DOC plus RAM) in second-line treatment of metastatic non-small cell lung cancer (NSCLC). (2015) (7)
- MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNOmics study (2021) (7)
- 1315PEfficacy and safety data from patients with advanced non-squamous NSCLC and brain metastases from the nivolumab expanded access programme (EAP) in Italy (2017) (7)
- Concise Review: Gene of The Month KEAP1-mutant non-small cell lung cancer: the catastrophic failure of a cell-protecting hub. (2022) (7)
- Use of HER2 gene amplification to identify patients with metastatic colorectal cancer resistant to anti-EGFR monoclonal antibodies. (2012) (7)
- Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program (2018) (7)
- Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives. (2020) (7)
- Activity of formestane in de novo tamoxifen-resistant patients with metastatic breast cancer. (1995) (6)
- Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts. (2020) (6)
- Ceritinib for the treatment of non-small cell lung cancer. (2014) (6)
- Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy (2016) (6)
- Impact of crizotinib on patient-reported general health status compared with chemotherapy in patients with no prior systemic treatment for advanced non-squamous ALK-positive non-small cell lung cancer (NSCLC). (2015) (6)
- MA07.06 Crizotinib in ROS1 Rearranged or MET Deregulated Non-Small-Cell Lung Cancer (NSCLC): Preliminary Results of the METROS Trial (2017) (6)
- Achievements and future developments of ALK-TKIs in the management of CNS metastases from ALK-positive NSCLC. (2016) (6)
- Efficacy of crizotinib in ROS1-rearranged lung cancer: The European experience. (2014) (6)
- PS01.53: First‐Line Atezolizumab Plus Chemotherapy in Chemotherapy‐Naive Patients with Advanced NSCLC: A Phase III Clinical Program: Topic: Medical Oncology (2016) (6)
- Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. (2012) (6)
- C1-04: A phase II study of RAD001 (everolimus) monotherapy in patients with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I) (2007) (5)
- Randomized phase II study of danusertib (D) in second-line metastatic castration-resistant prostate cancer (CRPC). (2011) (5)
- New targeted therapies for non-small-cell lung cancer (2009) (5)
- 892PTreatment beyond progression in patients with advanced RCC participating in the expanded access programme (EAP) (2017) (5)
- Host immune‐inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer and poor performance status receiving first‐line immunotherapy (2021) (5)
- HDAC7 promotes NSCLC proliferation and metastasis via stabilization by deubiquitinase USP10 and activation of β-catenin-FGF18 pathway (2022) (5)
- Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (2016) (5)
- IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations. (2018) (5)
- Secondary ROS1 mutations and lorlatinib sensitivity in crizotinib-refractory ROS1 positive NSCLC: Results of the prospective PFROST trial (2019) (5)
- Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer (2021) (5)
- How selecting best upfront therapy for metastatic disease?—Focus on ROS1-rearranged disease (2020) (5)
- KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges (2022) (5)
- Gemcitabine—Cisplatin chemotherapy followed by radiotherapy in locally advanced non-small cell lung cancer (nsclc): A phase II retrospective analysis (2000) (5)
- Is FISH floating or still swimming in the lung cancer ocean? (2011) (5)
- Immunotherapy and lung cancer: from therapeutic cancer vaccination to novel approaches. (2016) (5)
- Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study (2019) (5)
- The Human Epidermal Growth Factor Receptor (HER) Family: Structure and Function (2014) (5)
- P2.06-017 Amethyst NSCLC Trial: Phase 2 Study of MGCD265 in Patients with Advanced or Metastatic NSCLC with Activating Genetic Alterations in MET: Topic: Phase II + NK (2017) (5)
- PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting (2021) (4)
- miR128 and LET-7 microRNAs as potential biomarkers for selection of patients with metastatic colorectal cancer candidate to cetuximab/panitumumab therapy. (2011) (4)
- KEAP1 -Mutant NSCLC: The Catastrophic Failure of a Cell-Protecting Hub (2022) (4)
- Consequences of targeted treatments for second-line therapy. (2010) (4)
- P3.02c-095 Italian Nivolumab Expanded Access Programme: Efficacy and Safety Data in Squamous Non-Small Cell Lung Cancer Patients: Topic: IT Clinical (2017) (4)
- COVID‐19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience (2021) (4)
- HER2 Deregulation in Lung Cancer: Right Time to Adopt an Orphan? (2018) (4)
- Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care? (2021) (4)
- MA 10.06 Real-World Results in Non-Squamous Non-Small Cell Lung Cancer Patients: Italian Nivolumab Expanded Access Program (2017) (4)
- P1.06-006 Treatment beyond Progression in Patients with Advanced Squamous NSCLC Participating in the Expanded Access Programme (EAP): Topic: Advanced General (2017) (4)
- Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative. (2000) (4)
- EGFR, HER2, and phospho-Akt are not predictive factors for response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). (2006) (4)
- Minimizing Aircraft ECS Bleed Off-Take - Virtual Integrated Aircraft Applications (2016) (3)
- The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer (2021) (3)
- ATALANTE-1 randomized phase III trial, OSE 2101 versus standard treatment as second- or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients. (2019) (3)
- 9167 Outcomes with erlotinib in advanced NSCLC: examining the influence of increased EGFR gene copy number and EGFR mutations (2009) (3)
- Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non-Small-Cell Lung Cancer Whose Tumors Harbor Uncommon Epidermal Growth Factor Receptors Mutations (2016) (3)
- Effect of increased MET gene copy number on survival of surgically resected non-small cell lung cancer (NSCLC) patients (2008) (3)
- Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC. (2016) (3)
- PS-1FIRST-LINE CRIZOTINIB VS PEMETREXED + CISPLATIN/CARBOPLATIN IN ASIAN PATIENTS WITH ADVANCED ALK+ NSCLC IN PROFILE 1014 (2014) (3)
- Crizotinib in ROS1 rearranged or MET deregulated non-small-cell lung cancer (NSCLC): final results of the METROS trial. (2016) (3)
- Induction therapy for early-stage non-small-cell lung cancer. (2004) (3)
- Exploratory subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase III study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC). (2016) (3)
- Should all Stage IV Non-Small Cell Lung Cancer Be Treated Palliatively? (1999) (3)
- New platinum derivatives in advanced non-small cell lung cancer. (2002) (3)
- Contents Vol. 52, 1999 (2000) (3)
- Standardization of EGFR FISH in colorectal cancer: Results of an international, interlaboratory reproducibility ring study. (2011) (3)
- MA 03.06 Effect of 2L Ramucirumab after Rapid Time to Progression on 1L Therapy: Subgroup Analysis of REVEL in Advanced NSCLC (2017) (3)
- First-line treatment of non small cell lung cancer (2007) (3)
- Abstract CT126: Soluble HLA-G and -E (sHLA-G/E) as potential biomarkers of clinical outcomes in patients (pts) with advanced, refractory squamous (SQ) NSCLC treated with nivolumab (NIVO): CheckMate 063 (2017) (3)
- Abstract CT200: IMpower130: Progression-free survival (PFS) and safety analysis from a randomized phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab as first-line (1L) therapy in advanced non-squamous NSCLC (2019) (2)
- 1156PItalian nivolumab expanded access programme: real-world results in non-squamous non-small cell lung cancer patients (2017) (2)
- Management of non-small cell lung cancer: focus on erlotinib. Foreword. (2012) (2)
- 356TiPPhase III clinical trials of atezolizumab in combination with chemotherapy in chemotherapy-naive patients with advanced NSCLC (2015) (2)
- A Real-World Systematic Analysis of Driver Mutations’ Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant Setting (2022) (2)
- Guide to Targeted Therapies: Treatment Resistance in Lung Cancer (2015) (2)
- EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data? (2008) (2)
- ATALANTE-1 randomized phase III trial, OSE-2101 versus standard treatment as second or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients (2019) (2)
- Malignant pleural mesothelioma: The gemcitabine-vinorelbine combination in pemetrexed-pretreated patients (2008) (2)
- 1900P RAMES trial: A multicentre, double-blind, randomized, phase II study on gemcitabine plus ramucirumab versus gemcitabine alone as second-line treatment for advanced malignant pleural mesothelioma (MPM) (2020) (2)
- A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as fi rst-line therapy for metastatic non-small-cell lung cancer (2014) (2)
- Erlotinib after initial platinum-doublet chemotherapy in patients with epidermal growth factor receptor (EGFR) wild-type (WT) non-small cell lung cancer (NSCLC): Results of a combined patient-level analysis of the BR.21 and SATURN trials. (2013) (2)
- H04*Update of REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line (2L) treatment of stage IV non-small cell lung cancer (NSCLC) including subgroup analysis of histology (2015) (2)
- Time course of skin toxicity (tox) secondary to erlotinib (E) therapy in patients (pts) with non-small cell lung cancer (NSCLC) enrolled in the SATURN study. (2011) (2)
- EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients? (2007) (2)
- Guide to Targeted Therapies: EGFR Mutations in NSCLC (2014) (2)
- Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer (2023) (2)
- Chemoimmunotherapy for stage IV non-small-cell lung cancer - Authors' reply. (2019) (2)
- P-362 Role of mitogen-activated protein kinase (MAPK) and AKT as predictive factors for response to ZD 1839 therapy in non-small cell lung cancer (NSCLC) patients (2003) (2)
- Optimal front line treatment for European patients harboring EGFR mutations: Do longitude and race make a difference? (2012) (2)
- EGFR TKIs as maintenance therapy in NSCLC: Finding the old in the new INFORMation. (2012) (2)
- Is gemcitabine cost effective in cancer treatment? (2007) (2)
- MET exon 14 mutations in advanced lung adenocarcinoma: Frequency and coexisting alterations. (2017) (2)
- Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer (2014) (2)
- Angioside: The role of Angiogenesis and Hypoxia in Lung Neuroendocrine Tumours According to Primary Tumour Location in Left or Right Parenchyma (2022) (2)
- First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly ‘unfrail’ patients with advanced non-small-cell lung cancer: a multicenter phase II study (2012) (2)
- Analysis of Molecular Biomarkers in Resected Early-Stage Non-Small Cells Lung Cancer: A Narrative Review (2022) (2)
- How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team. (2018) (2)
- Should every lung cancer patient be tested for EGFR mutation? (2006) (2)
- Simulation of Aircraft Virtual Architecture - Bleed Off-Take and ECS (2017) (2)
- Crizotinib in ROS1 and MET Deregulated NSCLC—Response (2020) (2)
- The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects (2021) (2)
- Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration (2022) (1)
- 793 Multicenter phase II study of gemcitabine-oxaliplatin (GEMOX) chemotherapy in untreated locally advanced or metastatic non-small cell lung cancer (NSCLC) patients (2003) (1)
- [Role of gemcitabine in the treatment of advanced non-small cell lung cancer: review of the main phase II and phase III trials]. (2001) (1)
- MA14.06 Nivolumab in Never Smoker Patients with Advanced Squamous NSCLC: Results from the Italian Expanded Access Programme (EAP) (2017) (1)
- Gastrointestinal tumors, colorectal (2012) (1)
- O-143 Gemcitabine-oxaliplatin (GEMOX) chemotherapy as first-line treatment in advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II study (2003) (1)
- A clinical pharmacogenetic characterization of DPD polymorphisms for pre-treatment screening of patients candidates to fluoropyrimidine therapy (2014) (1)
- Association of KRAS mutations in cell-free circulating tumor DNA with occurrence of resistance to TKIs in NSCLC (2014) (1)
- Prediction of fluoropyrimidine toxicities by screening DPYD genetic variants. (2011) (1)
- Perioperative outcomes of robotic lobectomy for early-stage non-small cell lung cancer in elderly patients (2022) (1)
- Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences. (2022) (1)
- Clinicopathologic correlates of pembrolizumab efficacy in patients with advanced NSCLC and a PD-L1 expression of >= 50%. (2020) (1)
- 9006 ORAL Results of a Phase 2 Study of Gemcitabine/Cisplatin/lniparib (GCI) Versus Gemcitabine/cisplatin (GC) in Patients With Advanced NSCLC (2011) (1)
- Efficacy of the Irreversible EGFR-HER2 Dual Inhibitor Afatinib in Pretreated Lung Adenocarcinoma (2012) (1)
- Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma. (2022) (1)
- M03-02: Molecular predictors for epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): role of egfr gene amplification (2007) (1)
- P37.17 Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutations in Non-small Cell Lung Cancer (NSCLC): A Global Meta-analysis (2021) (1)
- Not enough can be enough: feasibility of the Idylla EGFR mutation test when reuse of stained tissue slides is the only option available (2021) (1)
- D2-07: Mechanisms of activating PI3K signaling in lung cancers that become resistant EGFR tyrosine kinase inhibitors (2007) (1)
- P3.02c-096 Use of Nivolumab in Elderly Patients with Advanced Squamous NSCLC: Results from the Italian Expanded Access Programme (EAP): Topic: IT Clinical (2017) (1)
- 9007 ORAL Phase II Study of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker, in Patients With EGFR FISH-positive Advanced NSCLC (2011) (1)
- EP08.01-030 Nivolumab+Ipilimumab Vs Platinum-Based CT+Nivolumab In Advanced Lung Squamous-Cell Carcinoma: The Randomized SQUINT Trial (2022) (1)
- EGFR-Targeted Therapies in Non-small Cell Lung Cancer (2014) (1)
- Circulating programmed death ligand-1 (PD-L1) in non-small cell lung cancer (NSCLC). (2017) (1)
- Intracranial efficacy of first-line crizotinib vs. chemotherapy in ALK-positive NSCLC (2015) (1)
- 127TiP PROPEL: A phase I/II trial of bempegaldesleukin (NKTR-214) in combination with pembrolizumab (pembro) in patients (pts) with advanced solid tumours (2019) (1)
- Clinical recommendations for EGFR mutation testing in non-small cell lung cancer (NSCLC): Results from a European workshop. (2010) (1)
- 1279P The prognostic value of chemotherapy-induced neutropenia (CIN) in patients with advanced non-small cell lung cancer (NSCLC) in the era of chemoimmunotherapy (CIT) (2021) (1)
- C-MET gene copy number variation (CNV) analysis by quantitative PCR (qPCR) assay in Caucasian patients with gastric cancer (GC). (2011) (1)
- 6015 POSTER DISCUSSION An International Consortium in Chemo-refractory Metastatic Colorectal Cancer Patients Shows Cetuximab Efficacy in Patients Harboring HER2 Gene Copy Number Gain (2011) (1)
- Integrating programmed cell death ligand 1 (PD-L1) and neutrophil to lymphocyte ratio (NLR) as predictive panel of response to nivolumab in non-small cell lung cancer (NSCLC). (2017) (1)
- P3.02c-038 First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naïve Patients with Advanced NSCLC: A Phase III Clinical Program: Topic: IT (2016) (1)
- KEAP1 and TP53 Mutations in Lung Cancer: More Is Better. Reply to: "Survival Analysis of TP53 Co-Mutations Should Be Interpreted More Cautiously". (2022) (1)
- 70MO Genomic profiling to expand precision cancer medicine in the real world: The ROME trial (2023) (1)
- 1226PDIMPACT OF CRIZOTINIB ON PATIENT-REPORTED SYMPTOMS AND GLOBAL QUALITY OF LIFE (QOL) COMPARED WITH PLATINUM BASED CHEMOTHERAPY IN PHASE III STUDY OF TREATMENT NAïVE ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC). (2014) (1)
- O-191 HER1-HER2-HER3 gene amplification and akt activation inpatients with advanced non-small cell lung cancer (NSCLC) treated with gefitinib (2005) (1)
- Abstract 4853: NRP2b, a unique isoform of NRP2, promotes aggressive lung cancer phenotypes (2017) (1)
- HER2 and HER3 genomic gain increases sensitivity to gefitinib in epidermal growth factor receptor positive advanced non-small cell lung cancer (2005) (1)
- Abstract P6-10-09: Mutational landscape of breast cancer patients in ROME trial: preliminary results (2023) (1)
- Medical treatment of brain metastases from lung cancer. (2002) (1)
- The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective Study (2022) (1)
- Role of Pembrolizumab in recurrent or metastatic head and neck carcinoma. (2020) (1)
- A clinical pharmacogenetic characterization of DPD polymorphisms for pre-treatment screening of patients candidates to fluoropyrimidine therapy (2014) (1)
- Methods for EGFR Mutation Testing (2014) (1)
- PUB076 Programmed Cell Death Ligand 1 and Neutrophil to Lymphocyte Ratio to Predict Response to Nivolumab in Non-Small Cell Lung Cancer (2017) (1)
- P1.14-03 Molecular Determinants for Lorlatinib Activity in ROS1 Positive NSCLC: Results of the Prospective PFROST Trial (2019) (1)
- Lung cancer patients with HER2 mutations treated with chemotherapy and HER2 targeted drugs: Results form the EUHER2 cohort study. (2015) (1)
- P1.03-050 Clinical Consequences, Quality of Life, and Management of Neutropenic NSCLC Patients in the REVEL Trial (2017) (0)
- 1298PCRIZOTINIB IN PATIENTS WITH LUNG CANCER AND ROS1 FUSION: RESULTS FROM THE EUROPEAN COHORT EUROS1. (2014) (0)
- Stefan Wuchty , of Knowledge The Increasing Dominance of Teams in Production (2009) (0)
- Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis (2021) (0)
- Adjuvant treatment of resected non-small cell lung cancer (1999) (0)
- Subject Index Vol. 52,1995 (1995) (0)
- Therapy options for advanced NSCLC (2015) (0)
- Micro-RNA signature differences in lung adenocarcinoma with specific driver alterations. (2013) (0)
- Application of Model Based Systems Engineering for the Conceptual Design of a Hybrid-Electric ATR 42-500: From System Architecting to System Simulation (2020) (0)
- HDAC7 promotes NSCLC proliferation and metastasis via stabilization by deubiquitinase USP10 and activation of β-catenin-FGF18 pathway (2022) (0)
- Alectinib and ALK-Positive Non-Small Cell Lung Cancer Q & A with (0)
- Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC: A phase IV study. (2017) (0)
- Garon et al 2014 Lancet Supplument (2014) (0)
- Induction treatments in marginally operable non-small cell lung cancer (1999) (0)
- MicroRNA signature to predict sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC). (2012) (0)
- Lung Cancer Update 2017: from the test tube to the bed (2018) (0)
- Atezolizumab: state of art and future perspective in non-small cell lung cancer treatment (2018) (0)
- Anaplastic lymphoma kinase 1 detected by immunohistochemistry in non-small cell lung cancer: a promising feature? (2010) (0)
- Poziotinib in Treatment-Naïve Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-label Phase 2 Trial (Cohort 4). (2023) (0)
- Expression of estrogen and progesterone receptors in breast metastases from malignant melanoma (1999) (0)
- Surrogate Predictive Biomarkers for Response to Anti-EGFR Agents: State of the Art and Challenges (2007) (0)
- Methodologies and Processes to Achieve Earlier Virtual Integration of Aircraft Systems (2015) (0)
- Resistance to EGFR TKIs (2015) (0)
- Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials (2023) (0)
- IPSOS: A Phase III, Global, Multicentre, Open-Label, Randomised, Controlled Study of First-Line Atezolizumab Versus Single-Agent Chemotherapy in Patients with Non-Small Cell Lung Cancer Ineligible for Treatment with a Platinum-Containing Regimen (2022) (0)
- Erratum to "Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts" [Radiother. Oncol. 135 (2019) 74-77]. (2019) (0)
- [Management of small cell lung cancer patient in the regions of Lazio, Umbria and Sardinia.] (2021) (0)
- Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer. (2015) (0)
- O.26 Glutamine (GLN) supplementation in cancer patients receiving chemotherapy: a double blind randomized study (1996) (0)
- MTE26.02 EGFR Targeted Therapies: Lessons Learned (2017) (0)
- Subgroup analysis of patients (Pts) refractory to first-line (1L) chemotherapy from REVEL, a randomized phase 3 study of docetaxel (DOC) with ramucirumab (RAM) or placebo (PBO) for second-line (2L) treatment of stage IV non-small-cell lung cancer (NSCLC). (2017) (0)
- Global named patient use (NPU) program of afatinib in heavily pretreated advanced NSCLC patients who progressed following prior therapies, including erlotinib or gefitinib (2017) (0)
- Resistance to crizotinib and therapeutic options (2015) (0)
- Capmatinib plus osimertinib versus platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIb/IIIc or IV EGFR-mutant, T790M-negative NSCLC harboring MET amplification. (2022) (0)
- Impact of IVS14+1G>A and 2846A>T DPYD polymorphisms on toxicity outcome of patients treated with fluoropyrimidine-containing regimens. (2013) (0)
- The interplay between PD-L1 and vimentin in NSCLC patients: An exploratory analysis. (2019) (0)
- Abstract CT559: Capmatinib plus osimertinib vs platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIB/IIIC or IV EGFR-mutant, T790M-negative NSCLC harboring MET amplification (2022) (0)
- Use of molecular screening for clinical trials with EGFR inhibitors (2006) (0)
- A few pills twice a day keep ALK-positive non-small-cell lung cancer at bay. (2017) (0)
- Optimizing Anti-EGFR Strategies in Cancer Treatment (2007) (0)
- 6088 POSTER KRAS and EGFR MicroRNAs Regulation and Cetuximab/Panitumumab Sensitivity in Metastatic Colorectal Cancer Patients (2011) (0)
- ALK rearrangement is an independent predictive factor of unexpected nodal metastasis after surgery in early stage, clinical node negative lung adenocarcinoma. (2023) (0)
- [Colorectal carcinoma: therapeutic approach in patients already treated with metastasis resection]. (1996) (0)
- 376 Oral doxifluridine plus leucovorin in elderly patients with advanced breast cancer (1995) (0)
- MTE 10.01 Bridging the Gap between Genomics and Clinics (2017) (0)
- Nit-picking around second line in EGFRwt NSCLC: just an academic effort. (2015) (0)
- EGFR Amplification in Lung Cancer: Time for Thawing the Frozen FISH? (2016) (0)
- P-632 Role of ZD 1839 in patients affected by metastatic NSCLC (2003) (0)
- Are the patients with metastatic non-small cell lung cancer curable? (1999) (0)
- Combi-TED: a new trial testing Tedopi® with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line. (2023) (0)
- P9 Metastatic melanoma clinically simulating primary breast carcinoma: a retrospective analysis (1999) (0)
- Metastases within the breast from extramammary primary solid tumors: a retrospective analysis (1999) (0)
- 787 Pharmacodynamic study of serum EGFR and HER2 in patients with non-small cell lung cancer treated with ZD 1839 (2003) (0)
- Comment on: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. Author's reply (2004) (0)
- The Role of ERBB Family Blockade in NSCLC (2014) (0)
- Epidermal Growth Factor Receptor Messenger RNAExpression , Gene Dosage , and Gefitinib Sensitivity in Non ^ Small Cell Lung Cancer (2006) (0)
- System Simulation for Autonomous UAV Design* (2021) (0)
- Phase III study with atezolizumab versus placebo in patients with malignant pleural mesothelioma after pleurectomy/decortication (AtezoMeso study). (2022) (0)
- Lung Cancer Update 2017: from the test tube to the bed. (2018) (0)
- M1* RESISTANCE TO EGFR TKIS AND SERUM PROTEOMIC PROFILE IN NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS (2008) (0)
- Abstract 3061: Micro-RNA signature differences in lung cancer patients withALKtranslocation,EGFRmutations andKRASmutations. (2013) (0)
- Quality of life (QoL) of OSE2101 in patients with HLA-A2+ non–small cell lung cancer (NSCLC) after failure to immune checkpoint inhibitors (IO): Final data of phase 3 Atalante-1 randomized trial. (2022) (0)
- FoRT 05-BEAT: A phase II randomized trial comparing atezolizumab versus atezolizumab + bevacizumab as first-line treatment in patients with PD-L1 high advanced/metastatic NSCLC. (2022) (0)
- Abstract 812: Lack of intra-tumoral heterogeneity in lung adenocarcinoma supports gene fusions involving ALK as early clonal events (2010) (0)
- Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP). (2010) (0)
- Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations (2018) (0)
- Methods for predicting clinical outcome for inhibitors of epidermal growth factor receptor for cancer patients (2005) (0)
- 366 Combined exploratory immunophenotyping and transcriptomic tumor analysis in patients treated with OSE2101 vaccine in HLA-A2+ advanced non-small cell lung cancer (NSCLC) from the ATALANTE-1 trial (2021) (0)
- Predictive and Prognostic Implications of EGFR Mutations (2014) (0)
- Abstract 3195: HMGA1 and HMGA2 over-expression in human lung carcinoma (2011) (0)
- Global named patient use (NPU) program of afatinib, an oral ErbB family blocker, in heavily pretreated advanced non-small cell lung carcinoma (NSCLC) patients who progressed following prior therapies, including erlotinib or gefitinib (E/G) (2016) (0)
- Analysis of PFS and OS from the Saturn Study According to EGFR IHC Status Using the H-Score Reading Method (2012) (0)
- Resistance to anti-angiogenic drugs and therapeutic options (2015) (0)
- Overcoming EGFR-TKI Resistance (2015) (0)
- Alectinib Resistance Through Amphiregulin Overexpression: Is Osimertinib the Best Candidate? (2020) (0)
- MYC gene copy number (GCN) and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal cancer (mCRC). (2012) (0)
- IBS01.02 Strategies Treatment After Oligoprogression (2019) (0)
- Abstract 3431: Molecular determinants of KRAS p.G12C inhibitor efficacy in advanced NSCLC (2023) (0)
- Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC. (2023) (0)
- The efficacy of the ALK inhibitor crizotinib as compared with standard chemo- therapy as first-line treatment for advanced ALK-positive non–small-cell lung can- (2019) (0)
- Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib (2006) (0)
- 1246P Hybrid capture-based assays in primary diagnostics of NSCLC patients: Results from the NEOlung study (2020) (0)
- 1666TiP Phase II study of berzosertib (M6620) + topotecan in patients with relapsed platinum-resistant SCLC: DDRiver SCLC 250 (2021) (0)
- Programmed death ligand 1 (PD-L1) expression status as prognostic factor in early stage non-small cell lung cancer (NSCLC). (2017) (0)
- PUB074 Programmed Death Ligand 1 (PD-L1) Expression in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC) (2017) (0)
- 228PPATTERN OF DIHYDROPYRIMIDINE DEHYDROGENASE GENETIC VARIANTS IN PATIENTS WITH VARIOUS DEGREES OF TOLERABILITY OF FLUOROPYRIMIDINE TREATMENT. (2014) (0)
- Molecular signature in malignant pleural mesothelioma (MPM): Preliminary data of Italian RAMES study. (2018) (0)
- 984P Relationship between RET fusion partner and treatment outcomes in patients (pts) with non-small cell lung cancer (NSCLC) from the phase I/II ARROW study and real-world data (RWD) (2022) (0)
- 1048P Molecular predictors of immunotherapy efficacy in lung squamous-cell carcinoma (LSCC): Results from the randomized prospective SQUINT trial (2022) (0)
- 1322PReal life experience with nivolumab in patients (pts) with advanced non-squamous NSCLC (nSq-NSCLC) exhibiting KRAS mutations: The Italian Expanded Access Program (EAP) (2017) (0)
- KRAS has a role in acquired resistance to EGFR-TKIs in NSCLC: an analysis on circulating tumor DNA (2015) (0)
- The role of interleukin-8 (IL-8) in predicting the outcome of metastatic colorectal cancer patients treated with aflibercept in combination to FOLFIRI: the FLIBER study. (2019) (0)
- 483TiP A Phase (Ph) III clinical program: 1L atezolizumab (atezo) plus chemotherapy (chemo) in chemo-naive advanced NSCLC (2016) (0)
- 120PSubgroup analysis of adenocarcinoma patients refractory to first-line chemotherapy from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non–small cell lung cancer (NSCLC) (2017) (0)
- P1.01-53 Bone Metastases and Efficacy of Immunotherapy in Patients with Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC) (2018) (0)
- 9084 Pemetrexed vs docetaxel as second-line in NSCLC: is there a difference between adenocarcinoma and squamous cell carcinoma? – a retrospective analysis of a single institution (2009) (0)
- EP16.03-040 Biomarkersatlas.com: the Italian NSCLC Precision Medicine Knowledge Data Base (2022) (0)
- M27The role of research nurse in translational studies: LUCAS experience (2015) (0)
- P1.04-45 Immune-Oncology Gene Expression Profiles Allow Lung Cancer Patients’ Stratification and Identification of Responders to Immunotherapy (2019) (0)
- PUB071 Circulating Programmed Death Ligand-1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC) (2017) (0)
- 1024P Net treatment benefit of OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in phase III Atalante-1 randomized trial (2022) (0)
- Authors & Collaborators _ RAISE study (2015) (0)
- PP01.54 ImmunoBlood: A Prospective Study Evaluating the Development of Anti-Checkpoint Inhibitor Antibodies in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy (2023) (0)
- Multicentre, double-blind, randomised phase II study evaluating gemcitabine with or without ramucirumab as II line treatment for MPM. (2018) (0)
- Nivolumab plus ipilimumab (NI) versus chemotherapy plus nivolumab (CN) in squamous cell lung cancer (SqCLC): The SQUINT trial (2019) (0)
- PC07.04 Debate 2: For Wild-Type NSCLC, Which Will Be the Preferred Strategy: IO alone versus Chemo + IO - Chemo + IO (2018) (0)
- 1266PQUALITY OF LIFE (QOL) RESULTS FROM THE PHASE 3 REVEL STUDY OF RAMUCIRUMAB + DOCETAXEL (RAM + DTX) VERSUS PLACEBO + DOCETAXEL (PL + DTX) IN ADVANCED/METASTATIC NSCLC PATIENTS (PTS) WITH PROGRESSION AFTER PLATINUM BASED CHEMOTHERAPY. (2014) (0)
- 1665P Genomic mutational landscape of solid tumors: Preliminary results from ROME trial (2022) (0)
- 1051P Radiotherapy (RT) and efficacy of immune checkpoint inhibitors (ICI), chemotherapy (CTx) and chemoimmunotherapy (CIT) in patients with non-small cell lung cancer (NSCLC) (2022) (0)
- Lack of effect of pegfilgrastim on anemia in breast cancer patients treated with dose-dense chemotherapy (2007) (0)
- Prognostic role of nitrotyrosines in surgically resected non-small cell lung cancer (NSCLC). (2011) (0)
- 3002 ORAL Comprehensive assessment of molecular markers predicting response to cetuximab therapy in colorectal cancer (2007) (0)
- 1019P Pattern of clinical activity of anticancer vaccine OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in phase III Atalante-1 randomized trial (2022) (0)
- P1.01-015 Crizotinib in ROS1 Rearranged or MET Deregulated Non-Small-Cell Lung Cancer (NSCLC): Final Results of the METROS Trial (2017) (0)
- PP 92 Clinical and genetic characterization of dihydropyrimidine dehydrogenase deficiency in fluoropyrimidine-treated patients carrying the DPYD*2A allele (2011) (0)
- P5-13-07: MET and Hepatocyte Growth Factor (HGF) Increased Gene Copy Number Is Associated to Trastuzumab Failure in HER2 Positive Metastatic Breast Cancer (MBC). (2011) (0)
- H02*Afatinib vs erlotinib as second-line therapy of patients with advanced SCC of the lung following platinum-based chemotherapy: OS analysis from the global phase III trial LUX-Lung 8 (LL8) (2015) (0)
- P1.14-26 ALK Fusion Variant Detection by Targeted RNA-Seq in TKIs Treated ALK-Positive Lung Adenocarcinoma (2019) (0)
- P1.01-15 ROS1-Rearranged Non-Small Cell Lung Cancer Is Associated with High Rate of Venous Thromboembolism: Analysis of The METROS Trial (2018) (0)
- P2.06-016 Phase 2 Study of Ramucirumab plus Weekly Docetaxel in Stage IV NSCLC Following Progression after Platinum-Based Chemotherapy: Topic: Phase II + NK (2017) (0)
- 56P The prognostic role of KRAS mutations in patients with early-stage lung adenocarcinoma after robotic lobectomy and systematic lymphadenectomy (2022) (0)
- Prognostic Relevance of Fibroblast Growth Factor Receptor 1 (FGFR1) Gene Copy Number in Pure Lung Squamous-Cell Carcinoma (2012) (0)
- P2.04-49 Nivolumab Plus Ipilimumab (NI) Versus Chemotherapy Plus Nivolumab (CN) in Squamous Cell Lung Cancer (SqCLC): The SQUINT Trial (2019) (0)
- Multimodality therapy for non-small cell lung cancer (NSCLC): ongoing Italian experiences in the adjuvant and neoadjuvant settings. (2001) (0)
- 89P A clinical- and biological-based nomogram to predict unforeseen nodal metastases in clinically node-negative, radically resected lung adenocarcinoma (2023) (0)
- P77.04 PROPEL: A Phase 1/2 Trial of Bempegaldesleukin (NKTR-214) Plus Pembrolizumab in Lung Cancer and other Advanced Solid Tumors (2021) (0)
- 74TiP Capmatinib plus osimertinib vs platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIB/IIIC/IV EGFR-mutant, T790M-negative, MET-amplified NSCLC (2022) (0)
- EP08.02-048 Crizotinib in ROS1+NSCLC: Long-term OS Analysis in Patients with Brain Metastases Included in the Phase II METROS Trial (2022) (0)
- Clinical and genetic characterization of dihydropyrimidine dehydrogenase (DPD) deficiency in fluoropyrimidine-treated patients carrying the DPYD*2A allele (2011) (0)
- Serum levels of interleukin 8 (IL-8) and other cytokines as predictors of the efficacy of aflibercept in combination with FOLFIRI in metastatic colo-rectal cancer patients: The FLIBER study. (2018) (0)
- P2.14-02 TP53 Mutations Affect Sensitivity to Lorlatinib in ROS1 Positive NSCLC: Final Results of the PFROST Trial (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Federico Cappuzzo?
Federico Cappuzzo is affiliated with the following schools:
